In a pilot study of circRNA expression profiles in 348 primary breast cancer tissue samples, Smid et al. found that circCNOT2 is a prognostic biomarker of aromatase inhibitor therapy in advanced breast cancer patients (Smid et al., 2019). The gene discussed is CYP19A1; the disease is breast carcinoma.